915019-53-3

Basic information

• Product Name: Benzeneacetonitrile, 4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-.alpha.,.alpha.-dimethyl-
• Synonyms: Benzeneacetonitrile, 4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-.alpha.,.alpha.-dimethyl-;2-(4-(8-broMo-2-oxo-2,3-dihydro-1H-iMidazo[4,5-c]quinolin-1-yl)phenyl)-2-Methylpropanenitrile;Benzeneacetonitrile, 4-(8-broMo-2,3-dihydro-2-oxo-1H-iMidazo[4,5-c]quinolin-1-yl)-a,a-diMethyl-;2-[4-(8-Bromo-2-oxo-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl]-2-methylpropionitrile;4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-alpha,alpha-dimethylbenzeneacetonitrile
• CAS NO: 915019-53-3
• Molecular Formula: C20H15BrN4O
• Molecular Weight: 407.2633
• EINECS: 200-258-5
• Mol File: 915019-53-3.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Density: 1.508g/cm³
• Refractive Index: 1.685
• Storage Temp.: 2-8°C
• PKA: 10.95±0.20(Predicted)
• CAS DataBase Reference: Benzeneacetonitrile, 4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-.alpha.,.alpha.-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, 4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-.alpha.,.alpha.-dimethyl-(915019-53-3)
• EPA Substance Registry System: Benzeneacetonitrile, 4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-.alpha.,.alpha.-dimethyl-(915019-53-3)

Safety Data

• Hazardous Substances Data: 915019-53-3(Hazardous Substances Data)

Usage

General Description

The chemical "Benzeneacetonitrile, 4-(8-bromo-2,3-dihydro-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl)-.alpha.,.alpha.-dimethyl-" is a complex organic compound. Its composition includes benzene acetonitrile and an imidazoquinolin compound with bromine atom at the 8th position. It also includes a 2,3-dihydro-2-oxo-1H subtype within its structure. Additionally, it contains two alpha-dimethyl groups. Information on its physical properties, uses, safety precautions, and other details are not readily available, likely indicating that it is a specialized or less common compound. The characterization of such chemicals often requires advanced knowledge in organic chemistry.

InChI:InChI=1/C20H15BrN4O/c1-20(2,11-22)12-3-6-14(7-4-12)25-18-15-9-13(21)5-8-16(15)23-10-17(18)24-19(25)26/h3-10H,1-2H3,(H,24,26)

Upstream product

• 915019-52-2 2-[4-(3-amino-6-bromo-quinolin-4-ylamino)-phenyl]-2-methyl-propionitrile 
• 530-62-1 1,1'-carbonyldiimidazole 
• 915019-51-1 2-(4-((6-bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile 
• 1201643-75-5 (E)-5-bromo-2-((2-nitrovinyl)amino)benzoic acid 
• 723281-72-9 6-bromo-4-chloro-3-nitroquinoline 
• 853908-50-6 6-bromo-3-nitroquinolin-4-ol 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 71825-51-9 4-(2-cyanoprop-2-yl)-1-nitrobenzene 
• 115279-57-7 2-(4-aminophenyl)-2-methylpropionitrile 
• 503-38-8 trichloromethyl chloroformate 
• 206257-39-8 6-bromo-4-chloroquinoline-3-carboxylic acid ethyl ester 
• 79607-23-1 ethyl 6-bromo-4-oxo-1,4-dihydro-quinoline-3-carboxylate 
• 101937-44-4 diethyl 2-((4-bromophenylamino)methylene)malonate 
• 106-40-1 4-bromo-aniline 

Relevant articles and documents

Development of a Robust Synthesis of Dactolisib on a Commercial Manufacturing Scale

The development of the robust synthesis of 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]-phenyl]propionitrile (dactolisib) on a commercial scale is described. The key step is a Pd-catalyzed Suzuki coupling of 2-[4-(8-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)-phenyl]-2-methyl-propionitrile to 3-quinoline boronic acid. A special focus is placed on reducing the amount of Pd catalyst used in the Suzuki coupling and purifying the crude drug substance, including removing traces of Pd.

RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.